pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ultragenyx Pharmaceutical Inc. ($RARE) · news · pharmadog
← back to Ultragenyx Pharmaceutical Inc.
News mentioning $RARE
826
stories
27d
Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending
fiercebiotech
27d
#ERS26: Beam says AATD base editing data hold up after one year
endpoints
27d
Hospitals pursue deals to ensure survival as Trump’s Medicaid cuts loom
stat
27d
STAT+: UnitedHealth executives shower high-ranking Democrat with donations ahead of midterms
stat
27d
STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
stat
27d
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
27d
BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
fiercebiotech
27d
STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation
stat
28d
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Sep 4, 26
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
stat
Sep 4, 26
STAT+: Top Boston hospitals clash over Medicare Advantage network after split
stat
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 4, 26
STAT+: After failure of Angelman syndrome drug, experts see hope in other experimental therapies
stat
Sep 4, 26
Ionis wins FDA approval of Alexander disease drug zilganersen
endpoints
Sep 4, 26
Foods Alive Recalls Organic Moringa Leaf Powder Because of Possible Health Risk
fda recalls
Sep 4, 26
10 life sciences startups selected for accelerator program
biospace
Sep 4, 26
STAT+: FDA takes another look at botanical drugs
stat
Sep 4, 26
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
stat
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 4, 26
Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
fiercebiotech
Sep 4, 26
Opinion: The FDA removed the red tape around one of the best drugs for children with schizophrenia. But the fear remains
stat
Sep 4, 26
Opinion: Make infectious disease data boring again
stat
Sep 3, 26
STAT+: Recipients of gene-edited pig kidneys successfully receive human organs
stat
Sep 3, 26
FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease
biospace
Sep 3, 26
STAT+: Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder
stat
Sep 3, 26
FDA Approves First Drug to Treat Alexander Disease
fda press
Sep 3, 26
An AI drug specialist zeroes in on rare forms of obesity
biopharma dive
Sep 3, 26
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
fiercebiotech
Sep 3, 26
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
biopharma dive
Sep 3, 26
STAT+: Seattle scientists launch $95 million AI biology effort
stat
← prev
page 7 of 28
next →
